-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanoform 1-9/2026 operating loss narrows 37% to EUR 10.48 million

PUBT·11/19/2026 06:17:02
Diffusion vocale
Nanoform 1-9/2026 operating loss narrows 37% to EUR 10.48 million
  • Nanoform Finland's Q3 2026 basic loss per share narrowed 50% year over year to EUR 0.03.
  • Revenue rose 9% to EUR 720,000, while total operating costs fell 40% to EUR 3.09 million.
  • Operating free cash flow improved 43% to EUR -2.59 million; September 30 cash totaled EUR 15.47 million.
  • A global CDMO agreement targets GMP readiness for biologics manufacturing in Germany during the second half of 2027.
  • The first UK marketing authorization application for nanoenzalutamide is imminent, with a potential market launch as early as 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanoform Finland plc published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.